SrasV1, Main, Exploration, bibRecord, 004437

Inhibition of feline (FIPV) and human (SARS) coronavirus by semisynthetic derivatives of glycopeptide antibiotics

Identifieur interne : 004437 ( Main/Exploration ); précédent : 004436; suivant : 004438

Inhibition of feline (FIPV) and human (SARS) coronavirus by semisynthetic derivatives of glycopeptide antibiotics

Auteurs : Jan Balzarini [Belgique] ; Els Keyaerts [Belgique] ; Leen Vijgen [Belgique] ; Herman Egberink [Pays-Bas] ; Erik De Clercq [Belgique] ; Marc Van Ranst [Belgique] ; Svetlana S. Printsevskaya [Russie] ; Eugenia N. Olsufyeva [Russie] ; Svetlana E. Solovieva [Russie] ; Maria N. Preobrazhenskaya [Russie]

Source :

Antiviral research [ 0166-3542 ] ; 2006.

RBID : Pascal:06-0491667

Descripteurs français

KwdFr :
- Animaux, Antibactériens (), Antibactériens (pharmacologie), Antibactériens (synthèse chimique), Coronavirus félin (), Coronavirus félin (physiologie), Effet cytopathogène viral (), Glycopeptides (), Glycopeptides (pharmacologie), Glycopeptides (synthèse chimique), Humains, Inactivation virale, Lignée cellulaire, Réplication virale (), Téicoplanine (), Téicoplanine (pharmacologie), Vancomycine (), Vancomycine (pharmacologie), Vancomycine (synthèse chimique), Virus du SRAS (), Virus du SRAS (physiologie).
MESH :
- pharmacologie : Antibactériens, Glycopeptides, Téicoplanine, Vancomycine.
- physiologie : Coronavirus félin, Virus du SRAS.
- synthèse chimique : Antibactériens, Glycopeptides, Vancomycine.
Pascal (Inist)
- Animaux, Antibactériens, Coronavirus félin, Effet cytopathogène viral, Glycopeptides, Homme, Humains, Inactivation virale, Lignée cellulaire, Réplication virale, Téicoplanine, Vancomycine, Virus du SRAS, Virus syndrome respiratoire aigu sévère, Glycopeptide, Antibiotique, Antiviral, Relation structure activité, Syndrome respiratoire aigu sévère, Vancomycine, Teïcoplanine, Virus péritonite infectieuse féline, Recherche développement, Eremomycine.
Wicri :
- topic : Homme, Antibiotique.

English descriptors

KwdEn :
- Animals, Anti-Bacterial Agents (chemical synthesis), Anti-Bacterial Agents (chemistry), Anti-Bacterial Agents (pharmacology), Antibiotic, Antiviral, Cell Line, Coronavirus, Feline (drug effects), Coronavirus, Feline (physiology), Cytopathogenic Effect, Viral (drug effects), Feline infectious peritonitis virus, Glycopeptide, Glycopeptides (chemical synthesis), Glycopeptides (chemistry), Glycopeptides (pharmacology), Human, Humans, Research and development, SARS Virus (drug effects), SARS Virus (physiology), Severe acute respiratory syndrome, Severe acute respiratory syndrome virus, Structure activity relation, Teicoplanin, Teicoplanin (chemistry), Teicoplanin (pharmacology), Vancomycin, Vancomycin (chemical synthesis), Vancomycin (chemistry), Vancomycin (pharmacology), Virus Inactivation, Virus Replication (drug effects).
MESH :
- chemical , chemical synthesis : Anti-Bacterial Agents, Glycopeptides, Vancomycin.
- chemical , chemistry : Anti-Bacterial Agents, Glycopeptides, Teicoplanin, Vancomycin.
- chemical , pharmacology : Anti-Bacterial Agents, Glycopeptides, Teicoplanin, Vancomycin.
- drug effects : Coronavirus, Feline, Cytopathogenic Effect, Viral, SARS Virus, Virus Replication.
- physiology : Coronavirus, Feline, SARS Virus.
- Animals, Cell Line, Humans, Virus Inactivation.

Abstract

Various semisynthetic derivatives of glycopeptide antibiotics including vancomycin, eremomycin, teicoplanin, ristocetin A and DA-40926 have been evaluated for their inhibitory activity against feline infectious peritonitis virus (FIPV) and human (SARS-CoV, Frankfurt-1 strain) coronavirus in cell culture in comparison with their activity against human immunodeficiency virus (HIV). Several glycopeptide derivatives modified with hydrophobic substituents showed selective antiviral activity. For the most active compounds, the 50% effective concentrations (EC₅₀) were in the lower micromolar range. In general, removal of the carbohydrate parts of the molecules did not affect the antiviral activity of the compounds. Some compounds showed inhibitory activity against both, whereas other compounds proved inhibitory to either, FIPV or SARS-CoV. There was no close correlation between the EC₅₀ values of the glycopeptide derivatives for FIPV or SARS-CoV.

Url:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7114212

Affiliations:

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Inhibition of feline (FIPV) and human (SARS) coronavirus by semisynthetic derivatives of glycopeptide antibiotics</title>
<author><name sortKey="Balzarini, Jan" sort="Balzarini, Jan" uniqKey="Balzarini J" first="Jan" last="Balzarini">Jan Balzarini</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Rega Institute for Medical Research, K.U. Leuven, Minderbroedersstraat 10</s1>
<s2>3000 Leuven</s2>
<s3>BEL</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
<placeName><region type="province" nuts="2">Province du Brabant flamand</region>
<settlement type="city">Louvain</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Keyaerts, Els" sort="Keyaerts, Els" uniqKey="Keyaerts E" first="Els" last="Keyaerts">Els Keyaerts</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Rega Institute for Medical Research, K.U. Leuven, Minderbroedersstraat 10</s1>
<s2>3000 Leuven</s2>
<s3>BEL</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
<placeName><region type="province" nuts="2">Province du Brabant flamand</region>
<settlement type="city">Louvain</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Vijgen, Leen" sort="Vijgen, Leen" uniqKey="Vijgen L" first="Leen" last="Vijgen">Leen Vijgen</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Rega Institute for Medical Research, K.U. Leuven, Minderbroedersstraat 10</s1>
<s2>3000 Leuven</s2>
<s3>BEL</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
<placeName><region type="province" nuts="2">Province du Brabant flamand</region>
<settlement type="city">Louvain</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Egberink, Herman" sort="Egberink, Herman" uniqKey="Egberink H" first="Herman" last="Egberink">Herman Egberink</name>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Institute of Virology, Faculty of Veterinary Medicine, University of Utrecht</s1>
<s2>Utrecht</s2>
<s3>NLD</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Pays-Bas</country>
<placeName><settlement type="city">Utrecht</settlement>
<region nuts="2" type="province">Utrecht (province)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="De Clercq, Erik" sort="De Clercq, Erik" uniqKey="De Clercq E" first="Erik" last="De Clercq">Erik De Clercq</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Rega Institute for Medical Research, K.U. Leuven, Minderbroedersstraat 10</s1>
<s2>3000 Leuven</s2>
<s3>BEL</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
<placeName><region type="province" nuts="2">Province du Brabant flamand</region>
<settlement type="city">Louvain</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Van Ranst, Marc" sort="Van Ranst, Marc" uniqKey="Van Ranst M" first="Marc" last="Van Ranst">Marc Van Ranst</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Rega Institute for Medical Research, K.U. Leuven, Minderbroedersstraat 10</s1>
<s2>3000 Leuven</s2>
<s3>BEL</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
<placeName><region type="province" nuts="2">Province du Brabant flamand</region>
<settlement type="city">Louvain</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Printsevskaya, Svetlana S" sort="Printsevskaya, Svetlana S" uniqKey="Printsevskaya S" first="Svetlana S." last="Printsevskaya">Svetlana S. Printsevskaya</name>
<affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Gause Institute of New Antibiotics, Russian Academy of Medical Sciences</s1>
<s2>Moscow</s2>
<s3>RUS</s3>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Russie</country>
<placeName><settlement type="city">Moscou</settlement>
<region>District fédéral central</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Olsufyeva, Eugenia N" sort="Olsufyeva, Eugenia N" uniqKey="Olsufyeva E" first="Eugenia N." last="Olsufyeva">Eugenia N. Olsufyeva</name>
<affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Gause Institute of New Antibiotics, Russian Academy of Medical Sciences</s1>
<s2>Moscow</s2>
<s3>RUS</s3>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Russie</country>
<placeName><settlement type="city">Moscou</settlement>
<region>District fédéral central</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Solovieva, Svetlana E" sort="Solovieva, Svetlana E" uniqKey="Solovieva S" first="Svetlana E." last="Solovieva">Svetlana E. Solovieva</name>
<affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Gause Institute of New Antibiotics, Russian Academy of Medical Sciences</s1>
<s2>Moscow</s2>
<s3>RUS</s3>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Russie</country>
<placeName><settlement type="city">Moscou</settlement>
<region>District fédéral central</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Preobrazhenskaya, Maria N" sort="Preobrazhenskaya, Maria N" uniqKey="Preobrazhenskaya M" first="Maria N." last="Preobrazhenskaya">Maria N. Preobrazhenskaya</name>
<affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Gause Institute of New Antibiotics, Russian Academy of Medical Sciences</s1>
<s2>Moscow</s2>
<s3>RUS</s3>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Russie</country>
<placeName><settlement type="city">Moscou</settlement>
<region>District fédéral central</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">06-0491667</idno>
<date when="2006">2006</date>
<idno type="stanalyst">PASCAL 06-0491667 INIST</idno>
<idno type="RBID">Pascal:06-0491667</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000452</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000538</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000459</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000459</idno>
<idno type="wicri:doubleKey">0166-3542:2006:Balzarini J:inhibition:of:feline</idno>
<idno type="wicri:Area/Main/Merge">004660</idno>
<idno type="wicri:source">PMC</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7114212</idno>
<idno type="RBID">PMC:7114212</idno>
<idno type="wicri:Area/Pmc/Corpus">000D89</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000D89</idno>
<idno type="wicri:Area/Pmc/Curation">000D89</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000D89</idno>
<idno type="wicri:Area/Pmc/Checkpoint">001105</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">001105</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:16675038</idno>
<idno type="wicri:Area/PubMed/Corpus">002248</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002248</idno>
<idno type="wicri:Area/PubMed/Curation">002248</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002248</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002136</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002136</idno>
<idno type="wicri:Area/Ncbi/Merge">001488</idno>
<idno type="wicri:Area/Ncbi/Curation">001488</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001488</idno>
<idno type="wicri:doubleKey">0166-3542:2006:Balzarini J:inhibition:of:feline</idno>
<idno type="wicri:Area/Main/Merge">004027</idno>
<idno type="wicri:Area/Main/Curation">004437</idno>
<idno type="wicri:Area/Main/Exploration">004437</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Inhibition of feline (FIPV) and human (SARS) coronavirus by semisynthetic derivatives of glycopeptide antibiotics</title>
<author><name sortKey="Balzarini, Jan" sort="Balzarini, Jan" uniqKey="Balzarini J" first="Jan" last="Balzarini">Jan Balzarini</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Rega Institute for Medical Research, K.U. Leuven, Minderbroedersstraat 10</s1>
<s2>3000 Leuven</s2>
<s3>BEL</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
<placeName><region type="province" nuts="2">Province du Brabant flamand</region>
<settlement type="city">Louvain</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Keyaerts, Els" sort="Keyaerts, Els" uniqKey="Keyaerts E" first="Els" last="Keyaerts">Els Keyaerts</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Rega Institute for Medical Research, K.U. Leuven, Minderbroedersstraat 10</s1>
<s2>3000 Leuven</s2>
<s3>BEL</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
<placeName><region type="province" nuts="2">Province du Brabant flamand</region>
<settlement type="city">Louvain</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Vijgen, Leen" sort="Vijgen, Leen" uniqKey="Vijgen L" first="Leen" last="Vijgen">Leen Vijgen</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Rega Institute for Medical Research, K.U. Leuven, Minderbroedersstraat 10</s1>
<s2>3000 Leuven</s2>
<s3>BEL</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
<placeName><region type="province" nuts="2">Province du Brabant flamand</region>
<settlement type="city">Louvain</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Egberink, Herman" sort="Egberink, Herman" uniqKey="Egberink H" first="Herman" last="Egberink">Herman Egberink</name>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Institute of Virology, Faculty of Veterinary Medicine, University of Utrecht</s1>
<s2>Utrecht</s2>
<s3>NLD</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Pays-Bas</country>
<placeName><settlement type="city">Utrecht</settlement>
<region nuts="2" type="province">Utrecht (province)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="De Clercq, Erik" sort="De Clercq, Erik" uniqKey="De Clercq E" first="Erik" last="De Clercq">Erik De Clercq</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Rega Institute for Medical Research, K.U. Leuven, Minderbroedersstraat 10</s1>
<s2>3000 Leuven</s2>
<s3>BEL</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
<placeName><region type="province" nuts="2">Province du Brabant flamand</region>
<settlement type="city">Louvain</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Van Ranst, Marc" sort="Van Ranst, Marc" uniqKey="Van Ranst M" first="Marc" last="Van Ranst">Marc Van Ranst</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Rega Institute for Medical Research, K.U. Leuven, Minderbroedersstraat 10</s1>
<s2>3000 Leuven</s2>
<s3>BEL</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
<placeName><region type="province" nuts="2">Province du Brabant flamand</region>
<settlement type="city">Louvain</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Printsevskaya, Svetlana S" sort="Printsevskaya, Svetlana S" uniqKey="Printsevskaya S" first="Svetlana S." last="Printsevskaya">Svetlana S. Printsevskaya</name>
<affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Gause Institute of New Antibiotics, Russian Academy of Medical Sciences</s1>
<s2>Moscow</s2>
<s3>RUS</s3>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Russie</country>
<placeName><settlement type="city">Moscou</settlement>
<region>District fédéral central</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Olsufyeva, Eugenia N" sort="Olsufyeva, Eugenia N" uniqKey="Olsufyeva E" first="Eugenia N." last="Olsufyeva">Eugenia N. Olsufyeva</name>
<affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Gause Institute of New Antibiotics, Russian Academy of Medical Sciences</s1>
<s2>Moscow</s2>
<s3>RUS</s3>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Russie</country>
<placeName><settlement type="city">Moscou</settlement>
<region>District fédéral central</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Solovieva, Svetlana E" sort="Solovieva, Svetlana E" uniqKey="Solovieva S" first="Svetlana E." last="Solovieva">Svetlana E. Solovieva</name>
<affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Gause Institute of New Antibiotics, Russian Academy of Medical Sciences</s1>
<s2>Moscow</s2>
<s3>RUS</s3>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Russie</country>
<placeName><settlement type="city">Moscou</settlement>
<region>District fédéral central</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Preobrazhenskaya, Maria N" sort="Preobrazhenskaya, Maria N" uniqKey="Preobrazhenskaya M" first="Maria N." last="Preobrazhenskaya">Maria N. Preobrazhenskaya</name>
<affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Gause Institute of New Antibiotics, Russian Academy of Medical Sciences</s1>
<s2>Moscow</s2>
<s3>RUS</s3>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Russie</country>
<placeName><settlement type="city">Moscou</settlement>
<region>District fédéral central</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Antiviral research</title>
<title level="j" type="abbreviated">Antivir. res.</title>
<idno type="ISSN">0166-3542</idno>
<imprint><date when="2006">2006</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Antiviral research</title>
<title level="j" type="abbreviated">Antivir. res.</title>
<idno type="ISSN">0166-3542</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Anti-Bacterial Agents (chemical synthesis)</term>
<term>Anti-Bacterial Agents (chemistry)</term>
<term>Anti-Bacterial Agents (pharmacology)</term>
<term>Antibiotic</term>
<term>Antiviral</term>
<term>Cell Line</term>
<term>Coronavirus, Feline (drug effects)</term>
<term>Coronavirus, Feline (physiology)</term>
<term>Cytopathogenic Effect, Viral (drug effects)</term>
<term>Feline infectious peritonitis virus</term>
<term>Glycopeptide</term>
<term>Glycopeptides (chemical synthesis)</term>
<term>Glycopeptides (chemistry)</term>
<term>Glycopeptides (pharmacology)</term>
<term>Human</term>
<term>Humans</term>
<term>Research and development</term>
<term>SARS Virus (drug effects)</term>
<term>SARS Virus (physiology)</term>
<term>Severe acute respiratory syndrome</term>
<term>Severe acute respiratory syndrome virus</term>
<term>Structure activity relation</term>
<term>Teicoplanin</term>
<term>Teicoplanin (chemistry)</term>
<term>Teicoplanin (pharmacology)</term>
<term>Vancomycin</term>
<term>Vancomycin (chemical synthesis)</term>
<term>Vancomycin (chemistry)</term>
<term>Vancomycin (pharmacology)</term>
<term>Virus Inactivation</term>
<term>Virus Replication (drug effects)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term>
<term>Antibactériens ()</term>
<term>Antibactériens (pharmacologie)</term>
<term>Antibactériens (synthèse chimique)</term>
<term>Coronavirus félin ()</term>
<term>Coronavirus félin (physiologie)</term>
<term>Effet cytopathogène viral ()</term>
<term>Glycopeptides ()</term>
<term>Glycopeptides (pharmacologie)</term>
<term>Glycopeptides (synthèse chimique)</term>
<term>Humains</term>
<term>Inactivation virale</term>
<term>Lignée cellulaire</term>
<term>Réplication virale ()</term>
<term>Téicoplanine ()</term>
<term>Téicoplanine (pharmacologie)</term>
<term>Vancomycine ()</term>
<term>Vancomycine (pharmacologie)</term>
<term>Vancomycine (synthèse chimique)</term>
<term>Virus du SRAS ()</term>
<term>Virus du SRAS (physiologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemical synthesis" xml:lang="en"><term>Anti-Bacterial Agents</term>
<term>Glycopeptides</term>
<term>Vancomycin</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Anti-Bacterial Agents</term>
<term>Glycopeptides</term>
<term>Teicoplanin</term>
<term>Vancomycin</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Anti-Bacterial Agents</term>
<term>Glycopeptides</term>
<term>Teicoplanin</term>
<term>Vancomycin</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Coronavirus, Feline</term>
<term>Cytopathogenic Effect, Viral</term>
<term>SARS Virus</term>
<term>Virus Replication</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antibactériens</term>
<term>Glycopeptides</term>
<term>Téicoplanine</term>
<term>Vancomycine</term>
</keywords>
<keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Coronavirus félin</term>
<term>Virus du SRAS</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Coronavirus, Feline</term>
<term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" qualifier="synthèse chimique" xml:lang="fr"><term>Antibactériens</term>
<term>Glycopeptides</term>
<term>Vancomycine</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Cell Line</term>
<term>Humans</term>
<term>Virus Inactivation</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Animaux</term>
<term>Antibactériens</term>
<term>Coronavirus félin</term>
<term>Effet cytopathogène viral</term>
<term>Glycopeptides</term>
<term>Homme</term>
<term>Humains</term>
<term>Inactivation virale</term>
<term>Lignée cellulaire</term>
<term>Réplication virale</term>
<term>Téicoplanine</term>
<term>Vancomycine</term>
<term>Virus du SRAS</term>
<term>Virus syndrome respiratoire aigu sévère</term>
<term>Glycopeptide</term>
<term>Antibiotique</term>
<term>Antiviral</term>
<term>Relation structure activité</term>
<term>Syndrome respiratoire aigu sévère</term>
<term>Vancomycine</term>
<term>Teïcoplanine</term>
<term>Virus péritonite infectieuse féline</term>
<term>Recherche développement</term>
<term>Eremomycine</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
<term>Antibiotique</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Various semisynthetic derivatives of glycopeptide antibiotics including vancomycin, eremomycin, teicoplanin, ristocetin A and DA-40926 have been evaluated for their inhibitory activity against feline infectious peritonitis virus (FIPV) and human (SARS-CoV, Frankfurt-1 strain) coronavirus in cell culture in comparison with their activity against human immunodeficiency virus (HIV). Several glycopeptide derivatives modified with hydrophobic substituents showed selective antiviral activity. For the most active compounds, the 50% effective concentrations (EC<sub>50</sub>
) were in the lower micromolar range. In general, removal of the carbohydrate parts of the molecules did not affect the antiviral activity of the compounds. Some compounds showed inhibitory activity against both, whereas other compounds proved inhibitory to either, FIPV or SARS-CoV. There was no close correlation between the EC<sub>50</sub>
 values of the glycopeptide derivatives for FIPV or SARS-CoV.</div>
</front>
</TEI>
<affiliations><list><country><li>Belgique</li>
<li>Pays-Bas</li>
<li>Russie</li>
</country>
<region><li>District fédéral central</li>
<li>Province du Brabant flamand</li>
<li>Utrecht (province)</li>
</region>
<settlement><li>Louvain</li>
<li>Moscou</li>
<li>Utrecht</li>
</settlement>
</list>
<tree><country name="Belgique"><region name="Province du Brabant flamand"><name sortKey="Balzarini, Jan" sort="Balzarini, Jan" uniqKey="Balzarini J" first="Jan" last="Balzarini">Jan Balzarini</name>
</region>
<name sortKey="De Clercq, Erik" sort="De Clercq, Erik" uniqKey="De Clercq E" first="Erik" last="De Clercq">Erik De Clercq</name>
<name sortKey="Keyaerts, Els" sort="Keyaerts, Els" uniqKey="Keyaerts E" first="Els" last="Keyaerts">Els Keyaerts</name>
<name sortKey="Van Ranst, Marc" sort="Van Ranst, Marc" uniqKey="Van Ranst M" first="Marc" last="Van Ranst">Marc Van Ranst</name>
<name sortKey="Vijgen, Leen" sort="Vijgen, Leen" uniqKey="Vijgen L" first="Leen" last="Vijgen">Leen Vijgen</name>
</country>
<country name="Pays-Bas"><region name="Utrecht (province)"><name sortKey="Egberink, Herman" sort="Egberink, Herman" uniqKey="Egberink H" first="Herman" last="Egberink">Herman Egberink</name>
</region>
</country>
<country name="Russie"><region name="District fédéral central"><name sortKey="Printsevskaya, Svetlana S" sort="Printsevskaya, Svetlana S" uniqKey="Printsevskaya S" first="Svetlana S." last="Printsevskaya">Svetlana S. Printsevskaya</name>
</region>
<name sortKey="Olsufyeva, Eugenia N" sort="Olsufyeva, Eugenia N" uniqKey="Olsufyeva E" first="Eugenia N." last="Olsufyeva">Eugenia N. Olsufyeva</name>
<name sortKey="Preobrazhenskaya, Maria N" sort="Preobrazhenskaya, Maria N" uniqKey="Preobrazhenskaya M" first="Maria N." last="Preobrazhenskaya">Maria N. Preobrazhenskaya</name>
<name sortKey="Solovieva, Svetlana E" sort="Solovieva, Svetlana E" uniqKey="Solovieva S" first="Svetlana E." last="Solovieva">Svetlana E. Solovieva</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004437 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004437 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:06-0491667
   |texte=   Inhibition of feline (FIPV) and human (SARS) coronavirus by semisynthetic derivatives of glycopeptide antibiotics
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

Serveur d'exploration SRAS

Inhibition of feline (FIPV) and human (SARS) coronavirus by semisynthetic derivatives of glycopeptide antibiotics

Inhibition of feline (FIPV) and human (SARS) coronavirus by semisynthetic derivatives of glycopeptide antibiotics

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.